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Tumour-associated protein carbonic anhydrase IX (CA IX) has two major forms. One is a cell-associated, transmembrane protein
seen on Western blots as a twin band of 54/58kDa, expressed in gastric mucosa and in several types of cancer. The other is a soluble
protein s-CA IX of 50/54kDa, which is released into the culture medium or into the body fluids, most likely by proteolytic cleavage of
the extracellular part from transmembrane and intracellular sequences. While TC media of CA IX-positive tumour cell lines or short-
term cultures of tumour explants contain a relatively high concentration of s-CA IX (20–50ngml
 1), the level of this antigen in blood
serum and urine of renal clear cell carcinoma patients is about 1000  lower. The concentration of CA IX in the blood and in urine
varies within wide limits and there is no obvious correlation with tumour size. After nephrectomy, s-CA IX is cleared from the blood
within a few days. Only an extremely low concentration of CA IX was detectable in the sera and in urine of control individuals.
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Carbonic anhydrase IX (CA IX) protein (previously named as MN
or MN/CA IX) is a cell membrane protein (Pastorekova ´ et al, 1992;
Za ´vada et al, 1993), which is ectopically expressed in various
human tumours, mostly carcinomas, for example, cervical, renal,
colorectal, lung, mammary and others (Liao et al, 1994, 1997;
Saarnio et al, 1998). It has been suggested that CA IX may serve as
a biomarker in early stages of tumorigenesis; now it is turning out
to be induced in certain tumours by hypoxia, which is connected
with poor prognosis (Chia et al, 2001; Giatromanolaki et al, 2001;
Koukorakis et al, 2001). In renal clear cell carcinoma (RCC),
synthesis of CA IX is switched on by the loss of suppressor gene
VHL (Ivanov et al, 1998). Until recently, the identification of CA IX
in formaldehyde-fixed, paraffin-embedded tumour sections has
been based on immunohistochemical analysis using MAb M75.
On the other hand, there were no reports on detecting CA IX in
body fluids of cancer patients. For the assays of soluble antigens,
which are usually present only in extremely low concentrations,
two antibodies are needed, preferably monoclonal, directed to
different epitopes. One of them serves for concentrating the
antigen and the other for its detection and quantitation. However,
all efforts to raise antibodies specific for epitopes different from
the M75 epitope have failed. This represented the crucial problem,
which we succeeded to solve.
Our approach was based on the following consideration:
sequencing of Car9, the mouse homologue of human CA9 gene,
revealed that the N-terminal, proteoglycan-like (PG) domain of the
protein shows almost no homology between man and mouse. The
carbonic anhydrase (CA) domain is relatively conserved in
evolution. Therefore, the mouse will recognise human PG as ‘non-
self’ and be able to respond to it immunologically, but it will not
produce antibodies reacting with human CA domain. However, mice
with the disrupted Car9 gene (knockout) should be able to produce
antibodies against different antigenic sites of the CA IX protein.
Indeed, Zat’ovic ˇova ´ et al (2003), taking advantage of Car9 / 
mice constructed by Ortova ´-Gut et al (2002), was able to produce a
series of potent monoclonal antibodies (mAbs) specific for
different antigenic sites, many of which are located in the CA
domain (e.g. the V-10 antibody used in this report). The epitope of
our original M75 antibody is located in the PG domain of CA IX
and its amino-acid sequence is PGEEDLP (Za ´vada et al, 2000).
Using newly obtained mAbs, we were able to develop tests for
the s-CA IX antigen. To start with, we decided to use tumour cell
cultures as an easy model system. The first set of questions we
started to ask were: (1) Do the tumour cells containing cell-
associated CA IX also shed this antigen into the medium during
cultivation? (2) Is the soluble form of CA IX different from cell-
associated molecules? (3) What is the concentration of CA IX in
the media? (4) Do short-term cultures of human tumours also shed
s-CA IX, and if they do, how much of it? (5) Can soluble CA IX be
detected in the serum and urine of the patients? (6) How fast is the
clearance of CA IX from the blood and from urine after surgical
removal of the tumour? (7) What is the dependence of CA IX
concentration in body fluids on the tumour size? (8) Do the blood
and urine of healthy individiuals also contain CA IX?
In the present experiments, we chose the patients with RCC
because these tumours usually express CA IX to a high level and in
a high proportion of the patients.
MATERIALS AND METHODS
Patients and controls
The study included 50 patients (28 men and 22 women, mean age
63. 2 years, range 36–79) with newly diagnosed RCC. All patients Received 7 February 2003; revised 9 June 2003; accepted 16 July 2003
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yroutinely underwent ultrasound and CT before surgery to obtain
information for the standard staging protocol. Serum and urine
from these patients were obtained before surgery and 5 days after
it. In some patients, a sample of tumour tissue after nephrectomy
was used for short-term RCC cultures. In all patients the diagnosis
was confirmed histologically. In total, 18 patients served as
controls; these had been admitted to the hospital for other
urological conditions than RCC (infections, urinary stones, other
urological tumours, etc.). Other control sera were obtained from
healthy blood donors. The study had been approved by the
Departmental Ethics Committee.
Cell and tumour cultures and media
The cell line HT29 (DSMZ ACC299) derived from colorectal
carcinoma and A498 (ATCC No. HTB-44) derived from RCC were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplied
with 10% foetal calf serum (FCS, Gibco). Short-term cultures of the
tumours were fresh tumour excisions cut in 1mm pieces, rinsed
with phosphate-buffered saline (PBS, pH 7.2), suspended in
DMEM with 10% FCS (about 50–100mg of fresh weight of
tumour fragments in 5ml of the medium) and incubated in 5cm
Petri dishes at 371C in a 5% CO2 incubator. Cell lysis buffer
constitutes PBS with 1% Igepal CA-630 (Sigma), 0.25% deoxycho-
late and proteinase inhibitors (1mM phenylmethylsulphonyl
fluoride and 200 trypsin-inhibiting units of Trasylol per ml).
Immunological reagents and methods
Monoclonal antibodies M75 specific for the PG region of CA IX
has been produced by Pastorekova ´ et al (1992) and V-10 specific
for CA domain, by Zat’ovic ˇova ´ et al (2003). The isotype of mAb
M75 is IgG 2b and that of V-10 is IgG 2a. The IgG was purified
from hybridoma TC fluid by affinity chromatography as previously
(Za ´vada et al, 2000). For the concentration of immune complexes
formed by the mAbs with CA IX, antigen from TC media or cell
extracts Protein A-Sepharose (Sigma) was used: the mAb-CA IX
complexes from human sera or urine were adsorbed to anti-mouse
IgG-Agarose (Sigma). The immunoperoxidase conjugate M75-Px
was prepared using the peroxidase labelling kit (Roche Diagnos-
tics, GmBH, Mannheim, Germany).
Immunoprecipitation of s-CA IX from human sera and urine
was carried out as follows: to 0.75ml of serum or 10ml of urine
(both clarified by centrifugation) were added 2mg of M75 IgG and
allowed to react for 60min at room temperature. Following this,
each sample was supplied with 50ml of 50% pre-washed anti-
mouse IgG agarose beads and the suspension was agitated in a
rotator for 4h or overnight at þ41C. Then the beads with bound
mouse IgG and immune complexes were centrifuged
(1200r.p.m.2min
 1), the pellet was resuspended in 1ml PBS with
0.05% Tween 20 (PBS-T, Sigma) centrifuged as above and the
beads were heated at 1001C for 5min in 60ml of Laemmli sample
buffer supplied with 1.5–2% of FCS (for reasons explained in the
last paragraph of Results).
ELISA The ‘sandwich’ was composed of these layers: (1)
Microtitre plates or strips were coated with mAb V-10 IgG,
5mgml
 1 in 50mM carbonate buffer pH 9.6 which was adsorbed
3h at room temperature, (2) test antigen dilutions in PBS with 1%
FCS were adsorbed overnight at þ41C, (3) M75-Px conjugate
1:5000 in PBS with 1% FCS was allowed to bind for 2h at room
temperature, (4) orthophenylene diamine (OPD, Sigma), 1mgml
 1
in 100mM phosphate/citrate buffer pH 5.0þ1mlml
 1 of 30% H2O2
(Sigma), was allowed to react 30min in the dark at room
temperature. After steps 1–3, the plates were washed  4 with
PBS-T. The reaction was terminated by adding two drops of 2 N
H2SO4 per well. We have used the MaxiSorp strips or plates
(NUNC, Denmark).
Western blot analysis Sodium dodecyl sulphate – polyacrylamide
gel electrophoresis and Western blotting were performed as
described before (Za ´vada et al, 2000). Carbonic anhydrase IX
antigen on the blots was visualised by M75-Px conjugate, followed
by enhanced chemiluminescence (ECL) and exposure to X-ray film
Medix XG (FOMA, Czech Republic), with maximum sensitivity to
yellow-green light.
RESULTS
Cell-associated and soluble CA IX in cell cultures
Various human tumour cell lines, when grown to a high density,
produce CA IX seen on Western blots as a ‘twin’ protein p54/58
(Pastorekova ´ et al, 1992; Za ´vada et al, 1993). The present results
are consistent with these reports (Figure 1). The HT29 cell line
derived from colorectal carcinoma shows 54 and 58kDa bands of
CA IX on Western blots. Media from these cell cultures also
contain CA IX, but the molecules of the soluble form are somewhat
shorter, with two bands of 50 and 54kDa. The total content of CA
IX in the cell extract is about 10x higher than in the medium, as
determined by ELISA (Figure 2). The A498 cells are poor
producers of CA IX.
CA IX in tumour extracts and in media of short-term
cultures of RCC
Western blots of the extracts from RCC tumours resemble blots of
tumour cell cultures. They also contain two bands of 54 and 58kDa
and the proportion of CA IX per total protein is somewhat lower
than in HT29 cells (Figures 1 and 2). All the six RCC tumour
extracts were strongly CA IX positive. Control kidneys and a non-
RCC tumour, an angiolipoma, did not contain any CA IX.
Shedding of s-CA IX was examined in short-term cultures: the
medium from a suspension culture of tumour fragments was
harvested after 2 days and analysed by ELISA and Western
blotting. Again, both the concentration and Mr of s-CA IX were
comparable with the cultures of permanent tumour cell lines such
as HT29.
CA IX in the serum of RCC patients
There were no problems with detection and quantitation of the CA
IX protein in extracts from cells or tumours and in culture media.
The concentration of CA IX was sufficient for direct analysis by
Western blotting or by ELISA. Control cell extracts or media
showed no false positivity or nonspecific bands.
However, it was necessary to concentrate the CA IX protein from
the sera and urine of RCC patients before gel electrophoresis and
Western blotting.
We tested 30 samples of sera from RCC patients, 14 sera of
patients with tumours other than RCC, six sera of nontumour
HT29 Tumours + controls
kDa M C M 
58
54
50
29 31 27 K1 49 50 59 K2 38 38 50 59
Media
Figure 1 Western blot analysis of CA IX in culture media or in extracts
from cells, tumours and control tissues. HT29: M¼medium, C¼cell
extract. Numbers above the remaining lanes¼codes for the patients; K1,
K2¼control kidneys; no. 27¼angiolipoma; all other lanes¼RCC. The
lanes were loaded with 25ml of media or with 12.5ml of cell or tumour
extracts adjusted to 1mg of total protein per ml.
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ypatients suffering from various urological diseases and 42 sera of
healthy blood donors. Sera evaluated as positive were found
mainly in the RCC group. Out of total 30 RCC sera, 12 scored as
‘positive’ (40%). The RCC group included one sarcomatous RCC,
which was CA IX positive. Among 14 non-RCC tumour patients,
one was positive (papillary carcinoma).
An example of our tests is shown in Figure 3 (top panel). There
does not seem to be a clear correlation between the tumour size
and the concentration of CA IX in the serum. All sera evaluated as
‘negative’, including sera of healthy blood donors, did in fact show
an extremely weak 50kDa band of s-CA IX, which became well
visible only after prolonged exposure of the blots.
To obtain more support for the presumed origin of blood s-CA
IX from the tumours, we tested several paired sera from RCC
patients before and after nephrectomy (Figure 3, bottom panel).
Indeed, in three cases the postoperation sera contained much less
of s-CA IX than the corresponding preoperation sera. One
exception was patient no. 68, showing a postoperation increase
of the s-CA IX level – but this patient underwent only a palliative
operation. Only a moderate decrease of s-CA IX was seen in patient
no. 104; in his case sample A was taken only 1 day after
nephrectomy, whereas in all other patients it was obtained 5 days
after operation.
CA IX in urine
The RCC patients excrete s-CA IX protein in urine (Figure 4). For
obvious reasons, we could afford concentrating the antigen from
10ml of urine (or from larger volumes if needed), and loading one
lane on the gel with an aliquot corresponding to 8ml. It is turning
out that a relatively high percentage (19/27¼70%) of the patients
excrete CA IX in urine. Mr of the protein is about the same as in
blood. Some of the urine samples showed additional bands of
intermediate size. In two strongly positive samples (nos. 50 and
54), there was an additional band of 62kDa. Control specimens of
urine from 25 healthy persons, two nontumour and three non-RCC
tumour urology patients were all CA IX negative.
The data on CA IX concentration in biological materials tested
in the course of these experiments are summarised in Table 1. The
figures for cell and tumour extracts and for TC media are based on
ELISA. The CA IX concentration in blood sera and in urine was
determined by densitometric reading of films exposed with
Western blots and calculated by a comparison with included
calibration with HT29 medium, titrated in ELISA. All these figures
must be taken only as very approximate, due to high biological
variability (density-dependent expression of CA IX in cell cultures,
volume of fluids consumed by the patients before providing the
1.8
1.4
1.6
1.2
0.4
0.2
0.0
0.6
0.8
1.0
10.001.00 0.10 0.01 0.100 0.010 0.001 10.001.00 0.10 0.01
CA IX (ng ml-1) Dilution of media µg ml-1 Total protein
ABC
A
4
9
0
Figure 2 ELISA test for CA IX antigen. The numbers of tumour
materials correspond to the patients in Figure 1. HT29 cells grew in a 5cm
Petri dish, supplied with 5ml of media, exchanged 2 days before harvest.
The extract from the cell monolayer in this culture contained 5mg of total
protein. Extracts from the tumours were prepared directly from the
excisions, without previous cultivation in vitro. Media from the cultures of
tumour fragments were harvested after 2 days. (A) Purified CA IX protein
(described in Za ´vada et al, 2000); (B) TC media; (C) extracts from cells
and tumours; J¼purified CA IX; K¼A498 cells; ’¼HT29 cells;
patients no. m¼38; .¼50; E¼59.
kDa
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200 100 50
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s-CA IX
(pg)
s-CA IX  in the serum
of RCC patients before (=B) and
after (=A) nephrectomy
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s-CA IX concentrated
from human sera
Calibration
s-CA IX (pg)
Figure 3 Carbonic anhydrase IX protein in the sera of RCC patients and
of control individuals. Each lane was loaded with immunoprecipitate
corresponding to original 0.6ml of the serum. Lane designation: C1–
C3¼healthy blood donors; 100¼stones in the urether; non-RCC
tumours: 39¼papillary carcinoma from renal cells, 103¼urothelial tumour
of renal pelvis, 121¼sarcomatoid renal carcinoma; all other sam-
ples¼RCC (the largest are no. 68¼2350cm
3, no. 36¼1466cm
3, no.
50¼725cm
3, and the smallest no. 102¼9cm
3, no. 112¼14cm
3).
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Figure 4 Carbonic anhydrase IX protein in the urine of RCC patients
and control individuals. Each lane was loaded with immunoprecipitate
corresponding to original 8ml of urine. Nontumour patients: nos. 45 and
48¼stones in the urether; non-RCC tumour patients no. 28 and
57¼angiolipoma and no. 39¼papillary carcinoma. All other sam-
ples¼RCC (the largest were no. 36¼1466cm
3, no. 50¼725cm
3, the
smallest no. 44¼1cm
3, no. 60¼12cm
3 and no. 38¼14cm
3).
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yurine for CA IX determination). Western blotting is only a
semiquantitative method and no clearcut borderline exists between
‘normal’ and ‘elevated’ concentrations of the antigen.
Recovery of CA IX 50 and 58kDa bands from the diluted
cell extract or TC medium
In the course of these experiments, we made an unexpected
observation, which is relevant mainly from the methodical point of
view, nevertheless, it cannot be omitted from this paper, since it
was also encountered but not explained in other laboratories.
The concentration of CA IX in the serum and urine of RCC
patients is too low to be detected without previous concentration.
Therefore, we tested how efficiently CA IX can be immunopreci-
pitated from diluted cell extracts or TC media of HT29 cells.
The result was somewhat puzzling (Figure 5). The original cell
extract or TC medium contained two bands of CA IX. However,
after addition of M75 antibody followed by PA-Sepharose beads
and low-speed centrifugation, no CA IX was detected in the
supernatant and all CA IX antigens were present in the pellet.
Surprisingly, it was seen only as a single band of 54kDa, no matter
whether it was from the cell extract or from the medium. The other
band had disappeared. When the pellets were mixed with
corresponding supernatants, the lost bands appeared again in
their original intensity. For re-appearance of the lost band, it was
sufficient to add FCS to a final concentration of 1–2%. This
observation suggests that FCS (or various other proteins) provides
some sort of steric support for CA IX on Western blots. In this
experiment, the p54 band did not disappear after adding the mAb
and Protein A–Sepharose and after centrifugation, most likely
because during migration in polyacrylamide gel electrophoresis
and blotting it overlaps with the denatured heavy chain of M75
IgG. Since this observation, we started to add 1.5–2% of FCS to
Laemmli sample buffer to extract CA IX from the immunopreci-
pitates and to dilute the samples before gel electrophoresis and
Western blotting.
DISCUSSION
CA IX is the only member of the family of CAs that shows a strong
association with several types of human cancer. Normally, it is
present only in mucosa of the alimentary tract, mainly in the
stomach, but on the other hand, its expression in the tumours is
ectopic as a rule. It is a relatively complex molecule, exerting at
least two functions. Both of them may be of importance in normal
alimentary tract as well as in tumours. One of them is enzymatic
activity; CA IX belongs to carbonic anhydrases with the highest
activity (Wingo et al, 2001). In addition, CA IX is a cell adhesion
molecule, most likely involved in cell-to-cell communication; its
binding site overlaps with the M75 epitope (Za ´vada et al, 2000).
Recently generated CA9 /  mice cast more light on the normal
function of CA IX protein: it consists in differentiation and growth
regulation of gastric mucosa (Ortova ´-Gut et al, 2002). The role of
CA IX in the chain of molecular events in the process of
oncogenesis remains to be elucidated. In certain types of tumours,
the expression of CA IX reflects hypoxia, resulting in a poor
prognosis (for review, see Harris, 2002).
The present paper is focused on the soluble form of the CA IX
protein shed by tumour cells. It answers all the questions listed in
the introductory paragraph: s-CA IX is being shed from the cells
into the culture medium, and compared with cell-associated
protein p54/58, it is somewhat shortened (to 50 and 54kDa). This
size corresponds to the extracellular part of the CA IX molecule,
which is composed of proteoglycan (PG)-like and CA domains that
have been cleaved off the rest of the molecule – the transmembrane
(TM) segment and intracellular (IC) tail of CA IX (Opavsky ´ et al,
1996). The s-CA IX contains both PG and CA domains, since it
reacts with both mAb M75 specific for PG and with MAb V-10
specific for the CA domain.
Shedding of CA IX is moderately efficient; 2 days after exchange,
the medium contains about 10% of the total amount of CA IX
compared with the cell monolayer (Figure 2). On the other hand, the
concentration of s-CA IX in the blood of RCC patients, even if they
carry very large tumours, is approximately 1000  l o w e rt h a ni nT C
media (Table 1). This shows that s-CA IX is rapidly cleared from the
blood. There may be several mechanisms of clearance; we have
demonstrated one of them – excretion in urine without any major
degradation (Figure 4). Concentration of the s-CA IX in the urine of
RCC patients corresponds approximately to that in the blood. An
apparently higher percentage of CA IX-positive samples of urine from
RCC patients (70%), compared with positive samples of serum (40%)
has two causes. One of them is a larger starting volume of urine for
concentrating CA IX protein, while the other is a relatively higher
level of CA IX in normal sera compared with control urine samples.
Possibly, some of CA IX could be degraded to smaller fragments;
we are aware of the existence of CA IX-related polypeptides of 20–
30kDa lacking the PG domain. However, their detection and
quantification will require other technical improvements. Two
urine samples – nos. 50 and 54 – contain an apparently larger
protein of 62kDa reacting with mAb M75. The significance of this
larger protein is not clear; it was not found in the blood or in the
tumour extract from the same patient.
At present, the quality of Western blots from blood and urine of
RCC patients appears to be satisfactory, but admittedly, Western
blotting is not really suitable as a diagnostic test for hundreds or
thousands of urine samples. The present results merely show that
development of appropriate methods is feasible and most likely
indeed worthwhile; they may find clinical application for
monitoring the patients after surgery and possibly could be
helpful in deciding upon the optimum method for therapy.
Table 1 Concentration of CA IX in biological materials
HT29 cell extract
a 4mgg
 1 total protein
Fresh RCC extract 0.5–2mgg
 1 total protein
Normal kidney extract Not detectable
HT29 TC medium
a 20–50ngml
 1
RCC TC media 20–50ngml
 1
Sera of RCC patients 20pg–3.6ngml
 1
Control sera 5–25pgml
 1
Urine of RCC patients 20pg–3ngml
 1
Control urine 0–2pgml
 1
aA 5-cm Petri dish corresponds to 5ml of medium or to 0.5mg total protein
extracted from the cell monolayer.
ABCDABCD
kDa
58
54
50
HT29 medium HT29 cell extract
Figure 5 Recovery of CA IX bands 50 and 58kDa from diluted fluids
after immunoprecipitation. A¼original TC medium or extract from HT29
cells. To the same antigens as in A was added mAb M75 (ascites fluid) and
Protein A-Sepharose and after appropriate incubation, the mixtures were
centrifuged and analysed; B¼supernatant; C¼pellet. With antigens from
the medium, BþC was mixed and analysed¼D; with antigen from cell
extract, to the pellet was added 2% FCS (¼D). All samples for the analysis
were adjusted to the same concentration of CA IX protein.
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